Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Clin Cancer Res. 2020 Aug 21;26(21):5668–5681. doi: 10.1158/1078-0432.CCR-19-3685

Table 2:

Demographic information for peripheral blood cohorts

Blood Cohort n(%)
Vanderbilt DFCI
Total 58 30
IHC Subtype
ER+ 27 (46.55%) 27 (90%)
PR+ 26 (44.82%) 27 (90%)
HER2+ 17 (29/31%) 0 (0%)
TNBC 21 (36.21%) 0 (0%)
Response
No NAC 24 (41.38%) 0 (0%)
pCR 10 (17.24%) 1 (3.33%)
RD 24 (41.38%) 29 (96.67%)
RCB I not recur 3 (10%)
RCB I recur 2 (6.67%)
RCB II not recur 7 (23.33%)
RCB II recur 4 (13.33%)
RCB III 13 (43.33%)
NAC
No TAXANE 7 (12.07%) 0 (0%)
TAXANE 27 (46.55%) 30 (100%)
No NAC 24 (41.38%) 0 (0%)